Correlation analysis of lymphocyte-monocyte ratio with pathological complete response and clinical prognosis of neoadjuvant chemotherapy in patients with breast cancer

被引:9
|
作者
Meng, Xiangyu [1 ]
Wang, Xueying [2 ]
Jiang, Cong [1 ]
Zhang, Shuai [3 ]
Cheng, Shaoqiang [1 ]
机构
[1] Harbin Med Univ Canc Hosp, Dept Breast Surg, Harbin 150081, Peoples R China
[2] Harbin Med Univ Canc Hosp, Dept Head & Neck Surg, Harbin 150081, Peoples R China
[3] Harbin Med Univ Canc Hosp, Dept Med Oncol 4, Harbin 150081, Peoples R China
来源
TRANSLATIONAL ONCOLOGY | 2022年 / 18卷
关键词
Lymphocyte-monocyte ratio (LMR); Breast cancer; Neoadjuvant chemotherapy; Pathological complete response; HER-2; INFLAMMATION; BIOMARKERS; PLATELET; NEUTROPHIL; SURVIVAL; PLR; NLR;
D O I
10.1016/j.tranon.2022.101355
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: Inflammation plays an important role in tumor proliferation, metastasis, and chemotherapy resistance. Peripheral blood lymphocyte-monocyte ratio (LMR) has been reported to be closely associated with the prognosis of many tumors, such as certain hematologic malignancies and gastric cancer. However, the association in breast cancer is still not clear. This study investigated the relationship between LMR with pathological complete response and clinical prognosis of neoadjuvant chemotherapy in patients with breast cancer, to provide convenient and accurate predictive indicators for pathological complete response (pCR) and prognosis. Methods: The clinicopathological data of 192 female breast cancer patients who received neoadjuvant chemotherapy and surgery in Harbin Medical University Tumor Hospital from January 2013 to August 2017 were retrospectively analyzed. Blood lymphocytes and monocytes were obtained by peripheral venous punctures. Results: Compared with the low LMR group, pCR was more easily obtained in the high LMR group (P=0.020); Subgroup analysis showed that patients with the high LMR and HER-2(+) group were more likely to obtain pCR (P=0.011). Univariate andmultivariate results showed that the overall survival (OS) and disease free survival (DFS) of the high LMR group were longer than that of the low LMR group. Conclusion: LMR and HER-2 status are correlated with pCR of neoadjuvant chemotherapy in breast cancer patients and are independent predictors of pCR after neoadjuvant chemotherapy in breast cancer patients. Meanwhile, both LMR and T stage of tumor are independent prognostic factors of breast cancer patients, with good predictive value.
引用
收藏
页数:9
相关论文
共 50 条
  • [1] Is it possible to predict the pCR with CBC? A commentary on "correlation analysis of lymphocyte-monocyte ratio with pathological complete response and clinical prognosis of neoadjuvant chemotherapy in patients with breast cancer" by Meng et al.
    Simsek, Eda Tanrikulu
    Bayram, Batuhan
    Yildirim, Alev
    Eskazan, Ahmet Emre
    TRANSLATIONAL ONCOLOGY, 2022, 20
  • [2] Lymphocyte-to-Monocyte Ratio is Associated with the Poor Prognosis of Breast Cancer Patients Receiving Neoadjuvant Chemotherapy
    Ma, Youzhao
    Zhang, Jingyang
    Chen, Xiuchun
    CANCER MANAGEMENT AND RESEARCH, 2021, 13 : 1571 - 1580
  • [3] Derived Neutrophil-to-Lymphocyte Ratio Predicts Pathological Complete Response to Neoadjuvant Chemotherapy in Breast Cancer
    Ocana, Alberto
    Chacon, Jose Ignacio
    Calvo, Lourdes
    Anton, Antonio
    Mansutti, Mauro
    Albanell, Joan
    Martinez, Maria Teresa
    Lahuerta, Ainhara
    Bisagni, Giancarlo
    Bermejo, Begona
    Semiglazov, Vladimir
    Thill, Marc
    Chan, Arlene
    Morales, Serafin
    Herranz, Jesus
    Tusquets, Ignacio
    Chiesa, Massimo
    Caballero, Rosalia
    Valagussa, Pinuccia
    Bianchini, Giampaolo
    Alba, Emilio
    Gianni, Luca
    FRONTIERS IN ONCOLOGY, 2022, 11
  • [4] The dynamic change of neutrophil to lymphocyte ratio is predictive of pathological complete response after neoadjuvant chemotherapy in breast cancer patients
    Dan, Jiaqiang
    Tan, Jinya
    Huang, Junhua
    Zhang, Xiaoli
    Guo, Yao
    Huang, Yunkun
    Yang, Jin
    BREAST CANCER, 2020, 27 (05) : 982 - 988
  • [5] Early changes of platelet-lymphocyte ratio correlate with neoadjuvant chemotherapy response and predict pathological complete response in breast cancer
    Dan, Jiaqiang
    Tan, Jingya
    Huang, Junhua
    Yuan, Zhiying
    Guo, Yao
    MOLECULAR AND CLINICAL ONCOLOGY, 2023, 19 (05)
  • [6] Association of immune inflammatory biomarkers with pathological complete response and clinical prognosis in young breast cancer patients undergoing neoadjuvant chemotherapy
    Li, Fucheng
    Wang, Youyu
    Dou, He
    Chen, Xingyan
    Wang, Jianan
    Xiao, Min
    FRONTIERS IN ONCOLOGY, 2024, 14
  • [7] Low pretreatment lymphocyte/monocyte ratio is associated with the better efficacy of neoadjuvant chemotherapy in breast cancer patients
    Peng, Yang
    Chen, Rui
    Qu, Fanli
    Ye, Ying
    Fu, Yong
    Tang, Zhenrong
    Wang, Yihua
    Zong, Beige
    Yu, Haochen
    Luo, Feng
    Liu, Shengchun
    CANCER BIOLOGY & THERAPY, 2020, 21 (02) : 189 - 196
  • [8] Is the Neutrophil-to-Lymphocyte Ratio a Predictive Factor of Pathological Complete Response in Egyptian Breast Cancer Patients Treated with Neoadjuvant Chemotherapy?
    Ebaid, Naglaa F.
    Abdelkawy, Khaled S.
    Said, Amira S. A.
    Al-Ahmad, Mohamad M.
    Shehata, Mohamed A.
    Salem, Heba F.
    Hussein, Raghda R. S.
    MEDICINA-LITHUANIA, 2025, 61 (02):
  • [9] Clinical and pathological predictors of recurrence in breast cancer patients achieving pathological complete response to neoadjuvant chemotherapy
    Asaoka, Mariko
    Narui, Kazutaka
    Suganuma, Nobuyasu
    Chishima, Takashi
    Yamada, Akimitsu
    Sugae, Sadatoshi
    Kawai, Saori
    Uenaka, Natsuki
    Teraoka, Saeko
    Miyahara, Kana
    Kawate, Takahiko
    Sato, Eichi
    Nagao, Toshitaka
    Matsubara, Yuka
    Gandhi, Shipra
    Takabe, Kazuaki
    Ishikawa, Takashi
    EJSO, 2019, 45 (12): : 2289 - 2294
  • [10] The dynamic change of neutrophil to lymphocyte ratio is predictive of pathological complete response after neoadjuvant chemotherapy in breast cancer patients
    Jiaqiang Dan
    Jinya Tan
    Junhua Huang
    Xiaoli Zhang
    Yao Guo
    Yunkun Huang
    Jin Yang
    Breast Cancer, 2020, 27 : 982 - 988